Current Affairs - State - Discussion

US-based pharmaceutical company Eli Lilly announced a $1 billion investment in Telangana, specifically Hyderabad, to expand manufacturing and global supply of medicines for diabetes, cancer, Alzheimer’s, and other conditions. The state was chosen for its strong life sciences ecosystem, skilled workforce, robust infrastructure, and industry-friendly policies. This investment builds on the company’s existing Global Capability Centre in Hyderabad and is expected to enhance India’s role in the global pharmaceutical value chain. Additionally, it will generate thousands of jobs, promote skill development, and strengthen academic-industry collaboration, boosting Telangana’s reputation as a pharmaceutical hub.